LACEY LICHTENSTEIN: Open Payments
NPI 1720477714 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$319 in 17 payments from 9 companies in 2025. Trend: 2023 $343 · 2024 $376 · 2025 $319
Food & beverage: $319
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 6 | $99 |
| Novartis Pharmaceuticals Corporation | 3 | $54 |
| UROGEN PHARMA, INC. | 2 | $45 |
| ABBVIE INC. | 1 | $27 |
| TOLMAR, INC. | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| COLOPLAST CORP | 1 | $16 |
Products named: GEMTESA, PLUVICTO, BOTOX, ELIGARD, Nubeqa, PROVENGE, ADSTILADRIN, Titan.
Industry payments across MS — which companies pay providers there.
